Entero Therapeutics Inc

Research Entero Therapeutics Inc (GRDX) on Bullrun: market cap USD 27.01M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 27.01M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 36.25K-USD 6.39M-USD 5.70M-1813.6%-4.16USD 899.78KUSD 2.26MUSD 24.94M
FY2024n/a-USD 18.06Mn/an/a-15.99USD 163.48KUSD 140.53K-USD 3.88M
FY2023n/a-USD 15.79Mn/an/a-47.88USD 3.71Mn/aUSD 3.60M
FY2022n/a-USD 14.63Mn/an/a-416.94USD 1.36Mn/aUSD 2.74M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 27.01Mn/an/an/a
20252025-12-31USD 15.67Mn/an/an/a
20242024-12-31USD 2.96Mn/an/an/a
20232023-12-29USD 6.56Mn/an/an/a
20222022-12-30USD 5.08Mn/an/an/a
20212021-12-31USD 21.85Mn/an/an/a

About Entero Therapeutics Inc

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Entero Therapeutics Inc's market cap?

Entero Therapeutics Inc's market capitalization is USD 27.01M.

What does Entero Therapeutics Inc do?

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.